Abivax S.A. Stock
Price
Target price
€6.52
€6.52
-1.510%
-0.1
-1.510%
-
12:36 / Tradegate
WKN: A14UQC / Name: Abivax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Abivax S.A. Stock
We can see a decrease in the price for Abivax S.A.. Compared to yesterday it has lost -€0.100 (-1.510%).
For the coming years our community has positive and negative things to say abot the Abivax S.A. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Valuation (undervalued/overvalued)" there were negative voices in the community.
Pros and Cons of Abivax S.A. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | -1.510% | - | - | - | - | - | - |
| Valneva SE | -0.510% | -1.007% | -3.709% | -27.119% | 29.081% | -70.415% | -26.417% |
| Nanobiotix | 3.760% | 13.333% | 46.358% | -11.423% | 50.136% | 11.055% | -47.066% |
| Transgene S.A. | -2.850% | 7.658% | 60.403% | -23.027% | 39.562% | -56.147% | -30.624% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting
EQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting
EQS-News: Abivax Presents First Quarter 2025 Financial Results
EQS-News: Abivax Presents First Quarter 2025 Financial Results
EQS-News: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
EQS-News: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis